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Morphine and related opioids are the mainstay of analgesic treatment, especially in 
patients suffering chronic pain. Besides their antinociceptive effects they may also 
exhibit anxiolytic-like properties that could contribute to pain relief. The 
pharmacological manipulation of the serotonergic system may not only modulate pain 
transmission and processing but also other behavioral effects of opioids. The present 
study aimed to analyze the effect of the concurrent treatment with citalopram, a 
selective serotonin reuptake inhibitor, on the antinociceptive, locomotor and anxiety-
related effects induced by acute and subchronic administration of morphine in mice. 
Citalopram (15 mg/Kg) enhanced the acute antinociceptive effects of morphine when 
concurrently administered as evidenced by a two-fold increase in the ED50 for the 
antinociceptive effect of morphine in the hot-plate test.  Chronic studies also revealed 
that concurrent citalopram treatment (15 mg/Kg) delayed the development of 
tolerance to the thermal antinociceptive effects of morphine. Additionally, morphine-
induced hyperlocomotion was potentiated by citalopram as assessed in the open-field 
test and in the spontaneous activity recording in the home cage, a behavioural 
outcome to which tolerance or desensitization was not developed. Interestingly, 
chronic administration of both drugs promoted an anxiolytic effect as evidenced by 
the increased central activity in the open field test. Future investigations on this 
pharmacological interaction, such as the possible translational research in clinics, 




















Pain modulation by opioids is intricately regulated by other neurotransmitter systems, 
essentially monoamines such as noradrenalin and serotonin. Both monoamines are 
generated in specific neurons allocated in discrete nuclei from the midbrain and brain 
stem which descending axonal projections reach those areas of the spinal cord 
involved in the transmission and processing of pain signals through different 
ascending nociception pathways (Millan, 2002; Ossipov et al., 2010). In this sense, 
the potentiation of monoamine neurotransmission by non-selective reuptake inhibitors 
such as tricyclic antidepressants (TCA) has been described as an effective therapeutic 
indication for the treatment of chronic pain either when used alone or in combination 
with other opioid analgesic drugs (Dharmshaktu et al., 2012; Knotkova and 
Pappagallo, 2007; Patetsos and Horjales-Araujo, 2016). Nociception studies 
conducted with experimentation animals have also described an antinociceptive effect 
of either non-selective monoamine as serotonin reuptake inhibitors, such as 
citalopram, on its own (Fasmer et al. , 1989, Gatch et al. , 1998), or as effective 
adjuvants to enhance the analgesic properties of some opioids compounds (Gatch et 
al., 1998, Larsen and Christensen, 1982, Larsen and Hyttel, 1985, Larson and 
Takemori, 1977, Sugrue, 1979). In addition, previous investigations carried out with 
rats assessed for thermal nociception described an increase of the analgesic effect 
together with a delay of the expression of morphine tolerance when this drug was co-
administered with either amitriptyline or venlafaxine, both of them 
noradrenaline/serotonin reuptake inhibitors (Ozdemir et al. , 2012) and also with 
fluoxetine, a serotonin selective reuptake inhibitor (Ozdemir et al. , 2011). These 

















essential element in the prevention of morphine tolerance upon sustained treatment. 
Moreover, it has been described that administration of 5-hydroxytryptophan, a 
precursor of serotonin, prior to morphine decreases the occurrence of tolerance to this 
opiate in mice (Contreras et al., 1973). Similarly, a more recent report demonstrated 
that the combination of morphine with fenfluramine attenuates the development of 
tolerance in rats chronically treated with morphine (Arends et al., 1998). On the other 
hand, preclinical and clinical studies have reported the modulatory role of opioidergic 
system in anxiety (Colasanti et al., 2011), a behavioral feature dependent on the 
serotonergic tone. In this regard, opioid agonists, especially morphine, have been 
shown to exhibit anxiolytic-like actions (Glover and Davis, 2008) that may also 
contribute to pain relief. Interestingly, the effect of the concomitant administration of 
serotonergic drugs upon these anxiolytic actions of morphine has not been addressed 
yet.  
Therefore, the aim of the present work is to further examine and characterize the 
effect of citalopram on morphine-induced antinociception in C57BL6 mice submitted 
to the hot-plate thermal test when acutely administered in terms of potentiation of the 
opiate response together with the modulation of the development of morphine 
tolerance after chronic treatment. Moreover, changes in other behavioral responses 
such as locomotion as well as exploratory and anxiety-related behaviors evoked by 
morphine alone and combined with citalopram were also evaluated by the open field 
test.  
 


















Morphine sulphate was supplied by Alcaliber S.A. (Madrid, Spain) and citalopram 
hydrobromide was generously gifted by H. Lundbeck A/S (Copenhagen, Denmark). 
 
2.2. Animals and experimental groups   
Experiments were conducted with 2–3-month old male C57BL/6 mice weighing 25–
30 g. All procedures were approved by the Animal Care Committee of the University 
of Cantabria and according to the Spanish legislation (RD 53/2013) and the European 
Communities Council Directive (2010/63/UE) on “Protection of Animals Used in 
Experimental and Other Scientific Purposes”. Food and water were given ad libitum. 
Development of tolerance experiments were conducted with four experimental groups 
according to the drug treatment, i.e., vehicle, morphine, citalopram and morphine plus 
citalopram, each of them comprised by 10 mice. Three independent experiments were 
completed (120 mice in total). Dose-response curves to determine the ED50 of 
morphine and morphine plus citalopram were carried out with seven dose groups 
including 3-4 animals per group. These experiments were independently performed 
five times (125 mice in total).  
 
2.3. Nociception assays 
Hot plate nociception test was carried out with a BIO-CHP apparatus (Bioseb, 
France). Animals were placed on a surface at 55 °C and the latency time for reaction, 
defined as paw-licking or jumping, was counted. After reaction, mice were removed 
immediately from the hot surface. A cut-off time of 30 sec was considered throughout 
all the assays. Each animal was submitted to two consecutive tests 2 min apart and the 

















either as hot-plate latency in seconds or as percentage of maximum possible effect 
(%MPE) and according to the following formula: 
 
     
                             
                             
       
 
All drugs were diluted in a saline solution (0.15 M NaCl) and administered via the 
intraperitoneal route. For development of tolerance assays, drugs were administered at 
9:00 a.m. and 5:30 p.m during 7 days at the following doses per injection: morphine 
30 mg/kg, citalopram 15 mg/kg, morphine plus citalopram were co-administered at 
their respective doses and vehicle group was injected with an equivalent volume of 
saline solution. Nociception test was conducted on a daily basis 45 min after the first 
injection (9:00 a.m.). The day before starting this experimental schedule, all the 
animals were subjected to the tests in absence of drug administration in order to 
evaluate their basal response. Dose response experiments to discern the ED50 of 
morphine administered alone or concomitantly with citalopram (15 mg/kg) were 
performed by acute injections of morphine at the following doses: 5, 10, 15, 20, 25, 
30 and 50 mg/kg. ED50 calculation was done by non-lineal regression using the 
GraphPad Prism Software (GraphPad, San Diego, CA, USA) according to the 





Mice spontaneous home-cage activity was evaluated with the Acti-System II device 

















animal movement. Animal activity was recorded during 1 hour. 
 
2.5. Open field test 
The open field apparatus was a brightly lit (350 lx) white wooden box 
(50 cm × 50 cm × 30 cm) with white floor and luminescent walls. Mice were released 
in the center of the apparatus for 5 min, and behavior was video-tracked by a 
computerized system (Any-maze Video-Tracking software, Stoelting Co., U.S.A.). 
Total distance travelled and time spent in the center area (30 cm × 30 cm) were 
considered for analysis. The test was conducted with those animals submitted to the 
development of tolerance schedule 2 h and 30 min after the first injection (9:00 a.m.) 
on day 1 and 7. 
 
2.6. Statistical analysis 
The statistical analyses were performed using Student's t-test, one-way or two-way 
ANOVA where appropriate. When effects of independent variables (dose, time), or 
interactions were significant, two-way ANOVA analysis was followed by Tukey's 
multiple comparisons post-hoc test. The type of statistical analysis is indicated in the 
results/discussion section and in the figure legends. The level of significance was set 
at p < 0.05. Graph editing and statistical analyses were performed using the GraphPad 
Prism Software (GraphPad, San Diego, CA, USA). 
 
3. Results  
3.1. Antinociceptive potentiation 

















mice were administered with different doses of this opioid agonist, ranging from 10 to 
50 mg/kg, and subsequently submitted to hot-plate test evaluation. The hot plate test 
is a thermal nociception assay that contemplates two behavioral components, i.e. 
mouse paw licking and jumping, resulting from the supraspinal integration of 
different neural processes (Le Bars et al., 2001).  Response measurements, considered 
as the reaction time of the first of any of those behavioral elements, were taken at 15 
min intervals during 2 hours. The graphical plot of these results (Figure 1A) reveals 
an evident dose response effect of morphine on thermal nociception that was 
confirmed by statistical analysis (two-way ANOVA for dose variable F(4,15)  = 8.832, 
p < 0.005); in this sense, morphine administered at 10 mg/kg resulted completely 
ineffective, compared to vehicle,  in terms of thermal antinociception whereas the 
maximal response, arbitrarily established at 30 sec to avoid animal tissue damage, 
was achieved at the highest doses, i.e. 40 and 50 mg/kg.  Regarding the time course of 
morphine antinociceptive effect (two-way ANOVA for time variable F(8,120) = 16.93, 
p < 0.0001), all the effective doses reached their maximal response between 45 and 60 
min after injection (Tukey´s multiple comparison tests P < 0.001) (Figure 1A). 
Equivalent experiments were conducted, combining various doses of morphine with 
citalopram administered at 15 mg/kg (Figure 1B). In this case we decided to use a 
lower range of morphine doses, from 5 to 20 mg/kg, because it was observed in 
previous pilot tests a substantial potentiation of the morphine antinociceptive effect 
when injected in combination with citalopram. The confirmation of this potentiation 
is evident in data shown in Figure 1B, where the lowest morphine dose (5 mg/kg) 
evoked a robust antinociceptive reaction compared to mice only treated with 

















response latency. When comparing the time course of the antinociceptive effect after 
morphine injection, responses observed with the combination of both drugs appears to 
be less sustained than the equivalent obtained when morphine was administered alone 
(Figure 1A and 1B), with the exception of the morphine highest doses in combination 
with citalopram, 15 and 20 mg/kg, where responses are more stable across the time 
after reaching the maximal value between 45 and 60 min (two-way ANOVA for time 
variable F(8,120) = 21.20, p < 0.0001). This fluctuation observed in the antinociceptive 
response throughout time is reflected by the absence of statistical significance when 
comparing the different doses (two-way ANOVA for dose variable F(4,15)  = 1.368, p = 
0.2917). According to these results, we designated 45 min as the time interval after 


















Figure 1. Time course of morphine antinociceptive effect evaluated by hot-plate test.  
Data in graphs represent different responses measured as the latency to appear thermal nociceptive 
reaction in mice treated either with different doses of morphine alone (A) or in combination with 
citalopram at 15 mg/kg (B). Insets indicate the different doses of morphine used in each treatment. 
Each point represents mean ± SEM (n = 4 mice). 
 
Next, morphine dose-response experiments to determine the extent of citalopram 
enhancement in thermal antinociception assays were carried out by acutely treating 
animals with a range of increasing doses of morphine from 5 to 50 mg/kg, either 
solely or in combination with citalopram at 15 mg/kg. Comparison of curves 
corresponding to both experimental conditions in a single graph (Figure 2) reveals a 
robust leftward shift of the curve obtained with animals treated with the combination 
of morphine plus citalopram, indicating the gain in potency of morphine when co-
administered with citalopram. Non-lineal regression analysis of sigmoid curves from 
independent experiments resulted in a ED50 = 24.50 ± 1.31 (mean ± SEM; n = 5 
experiments) for morphine that was significantly larger (t-student (8) = 4.329, p = 
0.0025) than the equivalent value obtained in morphine plus citalopram experiments, 




















Figure 2.  Evaluation of morphine dose-response effect on thermal nociception.   
Data represented as % MPE were obtained from mice acutely treated with different doses of morphine 
alone (filled symbols) or in combination with citalopram at 15 mg/kg (opened symbols) and submitted 
to hot-plate test. Each point represents mean ± SEM (n = 3-4 mice) 
 
3.2. Development of tolerance. 
In order to induce morphine tolerance to antinociception in the hot plate test, mice 
were chronically treated with morphine (30 mg/kg), citalopram (15 mg/kg) or 
concurrently with morphine plus citalopram by injecting them twice daily during 
seven days as described in the Methods section. Thermal nociception was evaluated 
every day 45 min after the first drug injection and results from one representative 
experiment expressed as the percentage of maximum possible effect (%MPE) are 
shown in Figure 3.  
 
 
Figure 3. Induction of morphine tolerance to thermal antinociception evaluated by hot-plate test.  
Data expressed as % MPE were obtained from mice treated chronically during 7 days with morphine 
(30 mg/Kg), citalopram (15mg/Kg), morphine plus citalopram and vehicle. Nociception was assessed in 
a daily basis during the treatment period.  * p < 0.01, ** p < 0.001 and *** p < 0.0001 vs vehicle group. 
♯♯♯ p < 0.0001 vs morphine group. +++ p < 0.0001 vs citalopram group (Tukey's multiple comparisons 
post-hoc test). Each point represents mean ± SEM (n = 10 mice). 
 

















time variable (F(6,120) = 42.34, p < 0.0001), the group treatment variable (F(3,35) = 
13.98, p < 0.0001) or the interaction between both variables (F(18,120) = 14.67, p < 
0.0001). Similarly as observed in prior acute treatments, animals treated with 
morphine at this dose and evaluated on the day 1 presented an increase in the reaction 
time of some 50 % of the maximal response and significantly different from the 
reaction evoked by the group treated with vehicle (Post-hoc test p < 0.001). This 
effect was completely absent on the second day of treatment and not significantly 
different to the response observed for the vehicle group during the following 5 days 
demonstrating, therefore, a rapid development of morphine tolerance in mice to this 
type of thermal nociceptive stimulus. In relation to citalopram treatment, the time 
course curve presented a profile comparable to that observed with morphine (Figure 
3), i.e., the acute administration on day 1 resulted in an antinociceptive response of 
some 50 % of the maximal response that was followed by values not different from 
the vehicle group during the next 6 days. Further actimetry experiments were 
conducted to evaluate the spontaneous activity of mice in their home cages 1 hour 
after drug administration in order to verify that the increment in locomotion observed 
in our experiments was due to the animal exposition to a novel environment.  
Actimetry tests (Supplemental Figure 1) resulted in a significant hyperlocomotion 
effect in animals treated either with morphine alone or in combination with 
citalopram (two-way ANOVA for treatment variable F(3,48) = 225.5, p < 0.0001). In 
contrast, treatment with only citalopram resulted in values significantly lower to those 
ones observed in groups treated with morphine (Post-hoc test for curve comparison, p 
< 0.0001) and not different to the vehicle control group.  

















antinociceptive reaction on the first day of treatment (Figure 3). In fact, this response 
was about two fold larger than the one observed with each of these drugs individually 
administered  (Figure 3, day 1) suggesting the summation of their effects in the final 
response.  Conversely, morphine plus citalopram reached an antinociceptive response 
of some 90% on day 2 regardless the lack of effect of each drug when separately used 
at this time point (Figure 3, day 2) ruling out any assumption that considers a final 
accumulative effect upon concurrent administration. This difference, although at a 
lesser but significant extent, was still detected on the third day delaying the 
manifestation of tolerance to the analgesic effect of morphine co-administered with 
citalopram until the day 4 of treatment (Figure 3).  
 
3.3. Actimetry evaluation. 
Further actimetry experiments were conducted to evaluate the spontaneous activity of 
mice in their home cages 1 hour after drug administration in order to verify that the 
increment in locomotion observed in our experiments was due to the animal 
exposition to a novel environment.  Actimetry tests (Figure 4) resulted in a significant 
hyperlocomotion effect in animals treated either with morphine alone or in 
combination with citalopram (two-way ANOVA for treatment variable F(3,48) = 225.5, 
p < 0.0001). In contrast, treatment with only citalopram resulted in values 
significantly lower to those ones observed in groups treated with morphine (Post-hoc 


















Figure4. Evaluation of mice spontaneous activity. Mice actimetry measurements were conducted in a 
daily basis in their habitual home cages 1 hour after treatment with morphine (30 mg/Kg), citalopram 
(15 mg/Kg), morphine plus citalopram and vehicle. 
 
3.4. Open field test assessment. 
Mice assessed for thermal nociception in experiments of morphine development of 
tolerance were also evaluated in the open field test on days 1 and 7 by recording their 
behavior within the apparatus during 5 min. Two parameters were taken into account 
when analyzing the final results, i.e., locomotor activity as total distance and central 
activity as time spent in central area. In good agreement with actimetry results, 
locomotor hyperactivity was also detected on the open field test in mice administered 
with morphine alone or in combination with citalopram (two-way ANOVA for 
treatment variable F(3,58) = 38.94,  p < 0.0001).  Moreover, posthoc analysis revealed a 
potentiation of morphine-induced hyperlocomotion by citalopram that persisted after 
7 days of treatment (p < 0.0001 morphine plus citalopram versus morphine alone on 
days 1 and 7) (Figure 5A). Regarding central activity, the combined treatment of 
morphine plus citalopram induced a significant anxiolytic effect as evidenced by an 
increase in this parameter, particularly on day 7 (two-way ANOVA for interaction 






















Early reports already described the augmentation of morphine antinociceptive effects 
in experimentation animals when citalopram was simultaneously administered. In this 
regard, hot plate nociception assays conducted with rats determined 10 mg/kg as the 
minimum dose of citalopram required for a significant increase in reaction times of 
morphine analgesia (Sugrue, 1979) and, interestingly, this potentiation was selective 
for morphine since no equivalent effects were observed with methadone and 
pethidine. Nevertheless, this was contradicted by later results also obtained with rats 
evaluated for thermal nociception by hot plate test (Larsen and Hyttel, 1985). The 
Figure 5.  Behavioural effects of morphine, 
citalopram and their coadministration in the open-
field test.   
Mice were administered with morphine (30 mg/kg), 
citalopram (15 mg/kg), morphine plus citalopram and 
vehicle. Locomotor activity (total distance) (A) and 
central activity (time in the center area) (B) were 
evaluated after drug administration during 5 min at days 
1 and 7. * p < 0.05, ** p < 0.01 and  *** p < 0.001 vs 
respective vehicle group; # p 0.05 < and ## p< 0.01 vs 
respective morphine group (Tukey's multiple 
comparisons post-hoc test). Each bar represents mean ± 

















potentiation of morphine analgesia by citalopram observed in the present work 
confirmed previous results in rats assessed in hot plate test and in mice evaluated in 
grid shock assays (Larsen and Christensen, 1982) although a precise analgesic 
potency of morphine in terms of ED50 was not previously resolved.  On the other hand, 
a more recent publication reported results in complete disagreement with those 
described herein and by others, since the combination of citalopram and morphine in 
acute and chronic treatments performed in mice not only resulted in a potentiation of 
morphine, but also caused a decrease of its analgesic effect in both tail-flick and hot 
plate tests (Pakulska and Czarnecka, 2001).   
It has been extensively described that chronic treatments with morphine, and other 
opioid compounds, leads to the development of tolerance to the analgesic effects of 
these drugs. The pharmacological basis of this manifestation is related with the 
functionality of mu opioid receptors, the main site of action of morphine, and the 
desensitization processes that take place upon sustained receptor activation (Williams 
et al. , 2013). Furthermore, other adaptive changes within the CNS resulting from the 
continued receptor stimulation by morphine concern alterations in the expression of 
different proteins at the cellular level or modifications in the connectivity of neurons 
involved in the nociception transmission and/or supraespinal integration (Christie, 
2008). The antinociceptive-like effect detected after the acute administration of 
citalopram observed in development of tolerance experiments (Figure 3) has not been 
consistently described in previous investigations regardless its possible participation 
as potentiator of morphine analgesia (Fasmer et al., 1989, Larsen and Christensen, 
1982, Larsen and Hyttel, 1985, Lee et al. , 2012, Sugrue, 1979). The reason for this 

















experimentation animals are subjected to a novel environment in order to generate 
paw thermal stimulation introducing, consequently, an additional element that might 
interfere the behavioral outcome considered as response, i.e. paw licking and/or 
jumping, and influencing therefore the final interpretation of experimental 
observations. In this sense, it has been previously described in the case of citalopram, 
along with other SSRIs, a specific increase of spontaneous locomotor activity 
mediated by 5-HT1B and 5-HT2A serotonin receptors associated with the exposition of 
animals to a novel environment only observed in mice and not when tested in rats 
(Brocco et al., 2002, Millan et al. , 2003). Interestingly, this induced hyperlocomotion 
completely disappeared when mice treated with a similar dose of citalopram were pre-
exposed to the activity chamber consisting in a white plexiglass cage different to the 
one where the animals were habitually housed. In our case, the hot plate apparatus 
containing plexiglass walls to impede animal evasion could be considered as the new 
environment responsible of the increase in the locomotion activity only observed in 
animals treated with citalopram the first day of treatment (see Supplemental Video 1). 
This generalized hyperactivity would delay the appearance of behavioral signs 
associated to thermal nociception (paw licking and/or jumping) and would augment, 
consequently, the latency of the response. As far as we know, the only previous 
investigation that used the hot-plate test to evaluate antinociceptive properties of 
citalopram in mice also described an 86% increase of the response latency when 
administered at 40 mg/kg while it was ineffective at 10 mg/kg (Fasmer et al., 1989). 
This dose-response effect of citalopram observed in nociception assays was similarly 
described by Brocco et al. in experiments conducted to investigate the 

















(Brocco et al., 2002). In relation to the effect on the development of morphine 
tolerance when administered in combination with citalopram, the significance found 
in the ANOVA when considering the interaction between both variables, i.e. 
treatment and time, indicates that the slope of the tolerance curve corresponding to 
morphine plus citalopram treatment is distinct from the equivalent one obtained when 
using morphine alone. This result suggests that citalopram, in addition of delaying the 
appearance of tolerance to morphine thermal antinociceptive effect, promotes a 
different mechanism of morphine tolerance development when concurrently used. 
Equivalent results were reported in thermal nociception experiments conducted with 
rats concomitantly treated with morphine plus fenfluramine and evaluated by tail flick 
test (Arends et al., 1998). With this respect, simultaneous acute administration of 
morphine and fenfluramine significantly enhanced the antinociceptive effect of the 
opiate by shifting morphine dose-response curves to the left. Additionally, in chronic 
treatments a delay of tolerance development was also observed when combining both 
drugs in a similar manner as described herein in mice exposed to hot plate test and 
treated with morphine plus citalopram. Pharmacokinetics determinations in this same 
study ruled out the possibility that the attenuation of morphine tolerance development 
facilitated by fenfluramine were due to a higher concentration accompanied by a more 
sustained presence of morphine and/or its active metabolites during the chronic 
treatment suggesting, therefore, that inhibition of morphine tolerance would occur 
mainly due to an interference with the pharmacological mechanism underlying the 
development of tolerance to this opiate (Arends et al., 1998). More recent reports 
have also confirmed this delay of tolerance development to the morphine thermal 

















fluoxetine and assessed with tail flick and hot plate tests (Ozdemir et al., 2011, 
Ozdemir et al., 2012). The biological basis underlying this enhancement of morphine 
antinociceptive potency along with the delay of tolerance development by serotonin 
reuptake inhibition is an issue that remains to be elucidated. Previous results excluded 
any direct effect promoted by SSRIs that may influence the affinity of morphine for 
opioid receptors (Hynes et al., 1985) or the functional properties of mu opioid 
receptors evaluated by [
35
S]GTPγS binding autoradiography upon DAMGO 
stimulation in rat brain (Hesketh et al. , 2008). Other investigations consisting in the 
inhibition of the enhancement of morphine effects by using antagonist compounds, 
i.e. mianserin and methysergide, suggested the participation of 5-HT2 receptor 
subtypes in these processes (Gatch et al., 1998, Lee et al., 2012). At this respect, we 
have previously described an augmentation of morphine potency in [
35
S]GTPγS 
binding assays using membranes from cells heterologously co-expressing human mu 
opioid (MOP) and 5-HT2A receptors when cells were pretreated with serotonin 
(Lopez-Gimenez et al. , 2008); intriguingly, this enhancement of morphine EC50 was 
not paralleled by DAMGO in equivalent experiments. Morphine is not capable to 
induce MOP receptor internalization upon its activation in several heterologous and 
native tissues at difference of what is observed with other agonist compounds (for a 
review on this topic see (Lopez-Gimenez and Milligan, 2010)). It has been largely 
hypothesized that morphine functional deficiency in terms of MOP receptor 
endocytosis might be involved in the molecular basis of the development of tolerance 
after sustained treatments (Berger and Whistler, 2010, Whistler, 2012). Moreover, we 
also described in these same cells that co-activation of 5-HT2A receptors facilitated the 

















described in an analogous experimental model expressing 5-HT2C receptors instead 
(Campa et al., 2015, Lopez-Gimenez et al., 2008). Although rather speculative in 
terms of translating in vitro results obtained from heterologous systems to native or 
physiological models, these results may suggest future approaches to further explore 
the biological mechanisms implicated in the improvement of morphine analgesia by 
enhancing serotonergic neurotransmission. Furthermore and according to a recent 
publication (Brenchat et al., 2011), additional possibilities should be taken into 
account in terms of considering other serotonin receptor subtypes, such as 5-HT7, that 
could mediate the action of the serotonin remaining in the synaptic cleft resulting 
from SSRI treatment. 
The open field test is a behavioral paradigm widely used to evaluate locomotor 
activity and anxiety levels in rodents. When mice are exposed to this new and 
challenging environment they are naturally inclined to thigmotaxis which is 
evidenced as the movement of the animal away from the center and towards the 
peripheral zone of the open field and closer to the limiting walls. In this sense, such 
behavior has been considered as an index of timidity (Walsh and Cummins, 1976), 
and it is assumed to be an indicator of animal fear/anxiety state. Contrarily, those 
animals that spent more time in the central region of the field are considered as less 
fearful or anxious than those ones that prefer the perimeter area (Stanford, 2007). 
Results obtained with mice treated with SSRI in anxiety behavioral tests present a 
dual component, i.e., acute administration of some SSRI induces anxiogenic effects 
(Birkett et al., 2011, Mombereau et al., 2010) whereas repeated treatment leads to an 
anxiolytic response dependent on CREB function (Mombereau et al., 2010). In the 

















open field tests, we do not observe any of these effects either in acute as in subchronic 
citalopram treatments. However, we detected an anxiolytic response upon sustained 
citalopram and morphine co-treatment that may be explained due to an additive effect 
of both drugs in terms of augmentation of serotonergic transmission. In this sense, 
previous neurochemical studies demonstrated an increase of extracellular serotonin in 
rodent brain after morphine administration (Tao and Auerbach, 1994). These 
anxiolytic-like properties observed after sustained citalopram and morphine co-
treatment may hold clinical significance since chronic pain is usually associated with 
depression and anxiety disorders (Huyser and Parker, 1999, McWilliams et al., 2003). 
Early investigations already described an excitatory effect elicited by morphine in rats 
that was not affected by tolerance development after chronic treatment (Babbini and 
Davis, 1972). Further studies conducted with mice characterized other behavioral 
traits in response to morphine such as Straub sign, i.e. contraction of the sacro-
coccygeus dorsalis muscle with protrusion of the perineum and elevation of the tail, 
extension rigidity of the hind legs accompanied by increased motor activity and 
animal running in circles in their cages (Shuster et al., 1975). An equivalent sterotypia 
was detected in mice from our study submitted to morphine treatment (See 
Supplemental Video). In particular, mouse strain C57BL/6 presents a considerably 
higher running response when compared to other strains (Oliverio and Castellano, 
1974, Shuster et al., 1975) and, at difference to what happens in relation to tolerance 
to the analgesic effects of morphine, this locomotion response presented sensitization 
after sustained treatment. Although the negative correlation between running and 
analgesia has been reproduced in different laboratories and mouse strains, some 

















running response (Oliverio and Castellano, 1974). In the present study morphine 
administration the first day of treatment evoked a locomotor response significantly 
higher than animals treated either with vehicle or citalopram. That hyperlocomotion 
remained at equivalent levels after 7 days of treatment, excluding any episode of 
sensitization or development of tolerance to this response in our case. As previously 
described (Popik, 1999), citalopram presented no effects on locomotor activity in 
mice. However, a significant potentiation of the hyperlocomotion effect caused by 
morphine was observed when both drugs were concurrently administered either on 
day 1 as on day 7 of treatment. A possible explanation to the augmentation of 
locomotion upon morphine treatment, that considers a neurochemical mechanism 
mediated by the enhancement of dopamine neurotransmission, was proposed after 
microdialysis studies in rats (Di Chiara and Imperato, 1988). However, later 
investigations on the relationship between morphine induced changes in locomotor 
activity and mesolimbic dopamine release conducted with three different mouse 
strains, including C57BL/6, found no correlation between these two variables, i.e. 
locomotion and dopamine release, in any of the considered strains (Murphy et al., 
2001). Previous results concerning the effect of drugs facilitating serotonergic 
transmission on the locomotion enhancement promoted by morphine treatment are 
also in contradiction with our present observations.  In this sense, chronic treatments 
combining fluoxetine and morphine in rats resulted in attenuation of the locomotor 
stimulating effects of morphine (Sills and Fletcher, 1997). Similarly, fluvoxamine 
reduced morphine-induced hyperlocomotion in mice in a dose dependent manner in 
parallel to the potentiation of its antinociceptive effects (Ise et al., 2001). This 

















SSRIs used in the different studies. Further investigations in the future should 
elucidate the reason for these discrepancies. 
In conclusion, in the present work we have fully characterized the interaction between 
citalopram and morphine in terms of functional response in a thermal nociception test 
and on behavioral responses. Citalopram enhanced the antinociceptive effects of 
morphine when concurrently administered in mice in two ways, i.e. by increasing its 
pharmacological potency and by attenuating the development of tolerance in 
sustained treatments. Additionally, hyperlocomotion induced by morphine is also 
potentiated by citalopram although no signs of tolerance or sensitization were 
observed in relation to this behavior. Interestingly, we firstly described that the 
combination of both drugs promotes an anxiolytic effect that is clearly evidenced in 
central activity measurements in the open field test after subchronic treatments. 
Future investigations on this pharmacological interaction, such as the possible 
translational research in clinics, might have consequences in future strategies for the 
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